10-Q: Semler Scientific Reports Q3 2024 Results, Revenue Declines Amidst Strategic Shift to Bitcoin

Sentiment:

Quarterly Report 5 November 2024 4:06 PM

Semler Scientific's Q3 2024 results show a decrease in revenue compared to the previous year, alongside a strategic move to adopt Bitcoin as its primary treasury reserve asset.

Capital raiseThe company filed a shelf registration statement on Form S-3, under which the company may, from time to time offer, issue and sell debt securities, common stock, units and/or warrants in one or more offerings with a total amount up to $150 million.The company filed an at the market offering prospectus covering the offering, issuance and sale of up to $50.0 million of common stock that may be issued and sold from time to time under the Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co.During the quarter ended September 30, 2024, the company sold an aggregate of 86,734 shares of common stock under the Sales Agreement for aggregate net proceeds (less sales commissions) of $2,536.

Worse than expectedThe company's revenue decreased by 17% year-over-year, indicating worse than expected results.The company's net income decreased by 29% for the nine months ended September 30, 2024, compared to the same period in 2023, indicating worse than expected results.

Summary

Semler Scientific reported a revenue of $13.5 million for the third quarter of 2024, a 17% decrease compared to $16.3 million in the same period of 2023.
Net income for Q3 2024 was $5.6 million, a slight increase from $5.5 million in Q3 2023.
The company's operating expenses decreased by 16% to $8.4 million in Q3 2024.
For the nine months ended September 30, 2024, revenue was $43.9 million, down from $53.1 million in the same period of 2023, and net income was $11.7 million, compared to $16.4 million in 2023.
The company has adopted Bitcoin as its primary treasury reserve asset, purchasing 1,018 bitcoins for $68.4 million, with a fair value of $64.5 million as of September 30, 2024.
The decrease in revenue is attributed to the introduction of volume pricing tiers for some of the largest customers and changes in Medicare Advantage reimbursement rates.
The company is seeking a new FDA 510(k) clearance for expanded use of its QuantaFlo device.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with declining revenues and a strategic shift to Bitcoin, which introduces both potential and risk. The company's cost management is a positive, but the overall sentiment is neutral to slightly negative due to the revenue decline and the inherent risks of the bitcoin strategy.

Positives

Operating expenses decreased by 16% in Q3 2024, indicating cost management efforts.
The company's net income saw a slight increase in Q3 2024 compared to the same period last year.
The company is actively pursuing a new FDA 510(k) clearance for expanded use of QuantaFlo, which could open new market opportunities.
The company has adopted a bitcoin treasury strategy, which they believe has the potential to generate outsize returns.

Negatives

Revenue decreased by 17% in Q3 2024 compared to the same period last year.
The company's cash, cash equivalents and restricted cash decreased significantly from $57.3 million at the end of 2023 to $6.7 million at the end of Q3 2024.
The company experienced an unrealized loss of $3.9 million from the change in fair value of its bitcoin holdings for the nine months ended September 30, 2024.
The company's largest customers account for a significant portion of revenue and accounts receivable, creating a concentration risk.

Risks

The company's reliance on a single product, QuantaFlo, poses a risk if it fails to achieve broad market acceptance.
Changes in healthcare reimbursement policies, particularly by CMS, could negatively impact the profitability of using QuantaFlo.
The company's bitcoin treasury strategy exposes it to the volatility of bitcoin prices and regulatory risks.
The company relies on a small number of suppliers and facilities for manufacturing, which could lead to supply chain disruptions.
The company faces competition from other medical device companies, which could lead to obsolescence of its products.
The company has had material weaknesses in its internal control over financial reporting in the past, and there is a risk of recurrence.
The company's bitcoin holdings are less liquid than cash and may not serve as a reliable source of liquidity.
The company is subject to cybersecurity risks that could result in the loss of bitcoin or sensitive data.

Future Outlook

The company is seeking a new FDA 510(k) clearance for expanded use of QuantaFlo and will continue to develop additional products and services. The company believes that bitcoin has the potential to generate outsize returns as it gains increasing acceptance as digital gold.

Management Comments

The company views bitcoin as a reliable store of value and a compelling investment.
The company believes that bitcoin has the potential to approach or exceed the value of gold over time.
The company believes that the growing global acceptance and institutionalization of bitcoin supports their view that bitcoin is a reliable store of value.

Industry Context

The company's shift to Bitcoin as a primary treasury asset is a notable move, reflecting a growing trend of companies exploring digital assets. The company's performance is also affected by changes in healthcare reimbursement policies, which is a common challenge in the medical device industry.

Comparison to Industry Standards

Semler Scientific's revenue decline contrasts with some medical device companies that have shown growth, but the company's strategic shift to Bitcoin is unique.
The company's operating expense reduction is a positive sign, but the overall financial performance is below some industry benchmarks.
The company's investment in Bitcoin is a high-risk, high-reward strategy that is not typical of most medical device companies.
The company's reliance on a single product is a risk, as many successful medical device companies have diversified product portfolios.
The company's financial performance is below that of companies such as Intuitive Surgical and Medtronic, which have more diversified product portfolios and established market positions.

Stakeholder Impact

Shareholders face increased risk due to the company's investment in Bitcoin and the volatility of its price.
Employees may be affected by changes in the company's strategy and financial performance.
Customers may be affected by changes in the company's product offerings and pricing.
Suppliers may be affected by changes in the company's manufacturing and supply chain.

Next Steps

The company will continue to seek a new FDA 510(k) clearance for expanded use of QuantaFlo.
The company will continue to develop additional complementary proprietary products in-house and seek out other arrangements for additional products and services.
The company will continue to purchase bitcoin as part of its treasury strategy.

Key Dates

Date	Description
September 2020	The company acquired a promissory note from NeuroDiagnostics Inc.
December 2020	The company agreed to convert the promissory note from NeuroDiagnostics Inc. into shares of preferred stock.
June 2022	The company loaned Mellitus an aggregate of $1,000 through the purchase of two senior secured promissory notes.
December 2022	The company entered into a senior convertible promissory note arrangement with Monarch.
March 2023	CMS issued the final 2024 rate announcement with payment changes for the Medicare Advantage and Part D prescription drug programs.
May 28, 2024	The company announced that its board of directors adopted bitcoin as its primary treasury reserve asset.
June 6, 2024	The company filed a shelf registration statement on Form S-3.
August 13, 2024	The company's shelf registration statement on Form S-3 became effective.
August 14, 2024	The board of directors of the company adopted a new stock option and incentive plan.
October 4, 2024	The company's stockholders approved the new stock option and incentive plan at the Annual Meeting of Stockholders.
October 31, 2024	There were 7,266,242 shares of the issuers common stock outstanding.

Keywords

Semler Scientific, QuantaFlo, Bitcoin, Vascular Testing, Medical Devices, FDA 510(k), Medicare Advantage, Reimbursement, Digital Assets, Healthcare Technology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.